Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial

Sarilumab is a human monoclonal antibody directed against the alpha subunit of the interleukin-6 receptor complex. In the MOBILITY phase III randomized controlled trial (RCT), sarilumab + methotrexate (MTX) treatment resulted in clinical improvements at 24 weeks that were maintained at 52 weeks in adults with rheumatoid arthritis (RA), who have inadequate response to MTX (MTX-IR). These analyses indicate the effects of sarilumab + MTX versus placebo on patient-reported outcomes (PROs) in this RCT. Patients (n = 1197) were randomized to receive placebo, sarilumab 150 or 200 mg subcutaneously + ... Mehr ...

Verfasser: Strand, Vibeke
Dokumenttyp: Artikel
Reihe/Periodikum: Arthritis research & therapy
Verlag/Hrsg.: London, BioMed Central
Sprache: Englisch
ISSN: 1478-6354
Weitere Identifikatoren: doi: 10.1186/s13075-016-1096-9
Permalink: https://search.fid-benelux.de/Record/olc-benelux-1986309622
URL: NULL
NULL
Datenquelle: Online Contents Benelux; Originalkatalog
Powered By: Verbundzentrale des GBV (VZG)
Link(s) : http://dx.doi.org/10.1186/s13075-016-1096-9
http://dx.doi.org/10.1186/s13075-016-1096-9
Wird geladen...